Robeco Institutional Asset Management B.V. Cuts Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Robeco Institutional Asset Management B.V. decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 49.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 146,000 shares of the pharmaceutical company's stock after selling 140,756 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.06% of Vertex Pharmaceuticals worth $70,784,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of VRTX. Sequoia Financial Advisors LLC increased its position in shares of Vertex Pharmaceuticals by 8.1% during the first quarter. Sequoia Financial Advisors LLC now owns 13,931 shares of the pharmaceutical company's stock worth $6,754,000 after acquiring an additional 1,041 shares during the last quarter. Pure Financial Advisors LLC raised its position in shares of Vertex Pharmaceuticals by 42.7% during the 1st quarter. Pure Financial Advisors LLC now owns 829 shares of the pharmaceutical company's stock worth $402,000 after purchasing an additional 248 shares during the period. Perigon Wealth Management LLC lifted its stake in Vertex Pharmaceuticals by 6.8% in the first quarter. Perigon Wealth Management LLC now owns 5,280 shares of the pharmaceutical company's stock valued at $2,560,000 after buying an additional 337 shares during the last quarter. Alpine Bank Wealth Management bought a new position in Vertex Pharmaceuticals in the 1st quarter worth about $102,000. Finally, HBK Sorce Advisory LLC increased its position in Vertex Pharmaceuticals by 5.5% in the 1st quarter. HBK Sorce Advisory LLC now owns 594 shares of the pharmaceutical company's stock valued at $288,000 after acquiring an additional 31 shares during the period. Hedge funds and other institutional investors own 90.96% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Leerink Partnrs cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 6th. HC Wainwright restated a "buy" rating and set a $550.00 price target on shares of Vertex Pharmaceuticals in a report on Monday. Leerink Partners reissued a "market perform" rating and issued a $503.00 price target (down from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Royal Bank Of Canada set a $420.00 price objective on shares of Vertex Pharmaceuticals and gave the company a "sector perform" rating in a research report on Tuesday, June 17th. Finally, Scotiabank cut their price objective on Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating on the stock in a research note on Tuesday, May 6th. Fourteen equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $513.14.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $443.40 on Friday. The firm has a market capitalization of $113.87 billion, a P/E ratio of -113.11 and a beta of 0.41. The stock has a fifty day moving average price of $455.45 and a two-hundred day moving average price of $459.02. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). The firm had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The firm's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $4.76 EPS. As a group, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.